receptor agonist on striatal dopamine release. Synapse 57:67-75, 2005
2) Casey DE:Affective disorders and Tardive Dyskinesia. Encephale 14:221-226, 1988
3) Dubovsky SL, Thomas M:Tardive dyskinesia associated with fluoxetine. Psychiatr Serv 47:991-993, 1996
4) Durif F, Vidaihet M, Bonnet AM, et al:Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1835-1858, 1995
5) 藤原晶子,都甲崇,山本かおり,他:塩酸セルトラリンの投与により口腔ジスキネジアが出現した老年期うつ病の1例.精神医学 49:1259-1262,2007
6) Gerlach J, Casey DE:Tardive dyskinesia. Acta Psychiatr Scand 77:369-378, 1988
7) Kapur S, Remington G:Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476, 1996
8) Leo RJ:Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449-454, 1996
9) Miller R, Guy C:Loss of striatal cholinergic neurons as a basis for tardive and Ldopa-induces dyskinesias, Neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34:713-738, 1993
10) Ohno Y, Ishida-Tokuda K, Ishibashi T, et al:Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol 49:213-219, 1997
11) Ossowska K:Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 54:299-312, 2002
12) Sandyk R, Kay SR, Awerbuch GI:Subjective awareness of abnormal involuntary movements in schizophrenia. Int J Neurosci 69:1-20, 1993
13) Stahl SM:Essential Pharmacology. Neuroscientific Basis and Practical Applications, Cambridge University Press, 2000